Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes         Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older, with stage 2 T1D compared to placeboAdditional regulatory reviews are ongoing across different disease stages by regulatory authorities around the world Paris, September 10, 2025- The Chinese National Medical Products Admi ...